InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 185091

Friday, 07/03/2015 6:17:02 PM

Friday, July 03, 2015 6:17:02 PM

Post# of 345599

Choe publicly backing PS Targeting (March 27, 2014) when state stated "This is where the trouble begins..." when PS flips to the outside of the cellular membrane. She seems to be raising the alarm "arms race" on these viruses below.



so Hyeryun Choe became a big PS Targeting backer back in March of 2014 and also received some money to investigate further. That is about $2.3 Million all to investigate PS = Phosphatidylserine, or shall we say flipped PS and flipped PS is "where the trouble begins"., according to Hyeryun's direct quote below.

-----------------------------------------------

Scripps Florida Scientist Awarded $2.3 Million to Study Dengue Fever and Related Viruses

JUPITER, FL – March 27, 2014 – The outbreak of dengue fever that infected some 20 people in Florida’s Martin County late last year unnerved many who feared the tropical disease had once again established a foothold in Florida. The last outbreaks occurred in 2009 and 2010 in Key West—before that, the disease hadn’t struck Florida in more than 70 years.

Now, scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded $2.3 million from the National Institutes of Health to study a category of viruses that cause dengue fever, West Nile, yellow fever and other diseases spread by mosquitoes and ticks. These diseases can result in flulike symptoms, extreme pain (dengue has been called “bone-break fever”) and, in some cases, encephalitis.

This family of viruses, called “flavivirus,” affect some 2.5 billion people worldwide and cause hundreds of thousands of deaths each year. There are no antiviral treatments and a just handful of vaccines that provide protection against only a few of these diseases.

The principal investigator for the new five-year study is TSRI Associate Professor Hyeryun Choe, who will lead the effort to understand the virus’s mode of infection and how new therapies might interrupt it.

“Flavivirus uses a very clever method of infection,” Choe said. “It’s like using a side door to enter a house when the front door is locked.”

The viruses take advantage of the process that normally occurs during programmed cell death. During programmed cell death (“apoptosis”), a lipid usually found on the inner side of the cell membranes, specifically phosphatidylserine (PS), shifts to the surface, making itself readily available to any passing cellular stranger. This is where the trouble begins.

When cells are dying from a flavivirus infection, their freshly exposed PS is grabbed by the exiting virus, and phagocytes—cells that devour invading pathogens and dead and dying cells—engulf the virus as if it were a dying cell. Once engulfed by the phagocyte, the virus quickly turns the cell's own biology on its head, forcing it to produce copies of the virus.

While some viruses (influenza A for example) do not use PS in their life cycle, the flavivirus exploits this opportunity to the hilt. Infection of cells by dengue or West Nile viruses is markedly enhanced when phagocytes express receptors that recognize and bind PS.

It appears, however, that flaviviruses use only a subset of these receptors. The high selectivity, and the potency with which some of these receptors promote flavivirus infection, suggest only a small number of receptors might be effectively targeted to treat these diseases.

“We want to understand which PS receptors contribute the most to flavivirus infections and how we might block them,” Choe said. “Our studies are designed to offer insights useful in the development of new therapies.”

http://www.scripps.edu/news/press/2014/20140327choe.html



-----------------------------------------------------

Now, wouldn't it be nice if others knew about this and it looks like Peter Kolchinsky certainly does and he certainly must have been asked about PS Targeting and all of this... is part of the reason why so many would like to conceal much of this information that is slowly reaching the masses.

----------------------------------------------------

Peter Kolchinsky as one of the Authors next to Hyerun Choe

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=99185608&txt2find=choe|bavituximab

---------------------------------------------------

a nice Harvard party it seems to be and heck, even Cramer went to Harvard night school... and Dr. Jack West (who lost all credibility with me...) because he must have ties that do not want to spread the good word of PS Targeting and went to Harvard as well. One Harvard grad that will help Hyeryun Choe further the research of PS Targeting will be = Mike Farzan. Now listen and read carefully and connect some behind the scenes dots:

Hyeryun Choe just rec'd $2.3 Million to further PS Targeting research back in March 2014, which this author reminds you of below... yet no digging deeper and where the trouble begins = flipped PS as I show you above!...and now Mike Farzan is awaiting some additional funds and for PS Targeting as well? I bet 100% yes. When he applied for those funds, do you think it included research that was based on his wifes PS Targeting research from the past year ?? Think of it hard and long, read the above article twice and below twice... and you will conclude a big yes!

....because not all Harvard grads like Dr. West or Cramer will twist the truths for their monetary benefits.

---------------------------------------------------

Married to Science

May 11, 2015

By Eric Sauter

When Hyeryun Choe and Mike Farzan first met at Harvard some 20 years ago, it was in a laboratory that, as Farzan remembers, was so small they were "either going to kill each other or fall in love."

Fortunately for everyone at Scripps Florida, it was the latter.

Now, both Farzan and Choe are scientists on The Scripps Research Institute’s (TSRI) Jupiter campus—they arrived in 2012—and both study the inner workings of various viruses in the Department of Immunology and Microbial Science, specifically how these viruses make their initial entry into the cell.

They aren't the only married couple to take up scientific residence at Scripps Florida—only the latest.

Being married scientists has its advantages, Choe said. Among other things, it makes conversation easy.

"It's very convenient for us because, even though I haven't really calculated it, I think one-third of conversation is still about our work—it used to be more," she said. "The fact that we can talk about it freely without worrying about the other person not understanding is really good. Other people say you should never marry a person with the same profession, but it worked out wonderfully for us."

There's a lot to talk about, too. Her laboratory recently received a $2.3 million grant from the National Institutes of Health to study a category of viruses that cause dengue fever, West Nile, yellow fever and other diseases spread by mosquitoes and ticks. These diseases can result in flulike symptoms, extreme pain (dengue has been called "bone-break fever") and, in some cases, encephalitis.

This is especially relevant in Florida, where the outbreak of dengue fever that infected some 20 people in Florida's Martin County late last year unnerved many who feared the tropical disease had once again estab­lished a foothold in Florida. The last outbreaks occurred in 2009 and 2010 in Key West—before that, the disease hadn't struck Florida in more than 70 years.

"The virus uses a very clever method of infection," Choe said. "It's like using a side door to enter a house when the front door is locked."

While Farzan is interested in viral invasion, his focus has been on other viruses that have also made the news—Ebola and HIV. He was one of several scientists from Scripps Florida who received more than $1 million in National Institutes of Health funding to research inhibitors that block the entry of the Ebola virus. The team, which includes researchers at the University of California, San Francisco, is now looking for approval to conduct animal testing. They hope to develop drugs that could be used to vaccinate those at risk or treat those with symptoms.

"We have limited funding, but we have made really good progress," Farzan said. "I'm told this is going in NIH's fast-track mechanism, so we're hoping to hear something in the not too distant future."

Farzan recently had a study on another well-known virus—HIV—published by the prestigious journal Nature. The study, which, research-wise, was nearly a decade in the making, made a splash when it showed the team’s drug candidate could block every strain of HIV-1, HIV-2 and SIV (simian immunodeficiency virus) that has been isolated from humans or rhesus macaques, including the hardest-to-stop variants. (See “Scientists Announce Anti-HIV Agent So Powerful It Can Work in a Vaccine”)

Farzan finds being married to a scientific equal a blessing as well.

"Scientifically, it's as good as it gets because you're married to the collabo­rator that you trust the most," he said. "Sometimes it seeps into the marriage half of life—and sometimes work creeps too much into life. But on balance I would call it a good thing. It's no question that it helps the marriage—it strengthens it because you're with somebody who knows all aspects of you."

Having settled into a condo on the beach in Juno Beach, both are glad to be at Scripps Florida—and in Florida.

They walk on the beach—Choe admits that Farzan does it more than she does—and that she was a little worried about how hot it would be when they finally settled into the Sunshine State.

"I thought it would be too hot and too humid," she said, "but we adapted to it so fast and now we can't live anywhere else. It's so funny that I worried about the weather."

http://www.scripps.edu/newsandviews/e_20150511/choe_farzan.html



------------------------------------------------------

Now, for the last time, don't you think its quite significant that the latest article where Mike Farzan is awaiting funding for HIV/Ebola..etc just may place PS Targeting on the map for good? Do you think it is foolish for some to keep reminding you of dilution or the old times... and some don't like to remind you of "where the trouble begins = flipped PS" ???

Read them both again, slowly.... and will Peregrine require 4 Billion shares to handle the demand in soon enough time? Hell yes.

Would you want to buy at $10..or $15..or higher.. vs $1.30 ? Well that is up to you after doing your own due diligence.

Now back to mowing some lawns and damn, Richard Lerner to Michael Marletta ... and Sanofi Sunrise Katherin Bowdish and team all coming together in 2014 as well. These puzzle pieces play a part as well.




"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News